Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor

May 28, 2006 at 9:34 pm Leave a comment

Agents and Chemotherapy 1 Jun 2006 Vol.50 N.6 p.2201-2206

Susan L. Ford,1* Y. Sunila Reddy,1 Maggie T. Anderson,1 Sharon C. Murray,1 Pedro Fernandez,1 Daniel S. Stein,2 and Mark A. Johnson1

GlaxoSmithKline, Research Triangle Park, North Carolina,1 Sanofi-Aventis Pharmaceuticals, Bridgewater, New Jersey2

Clic ver abstract:
http://aac.asm.org/cgi/content/abstract/50/6/2201

Advertisements

Entry filed under: HIV/SIDA HAART.

Fluoroquinolone-Resistant Urinary Isolates of Escherichia coli from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Calendar

May 2006
M T W T F S S
« Apr   Jun »
1234567
891011121314
15161718192021
22232425262728
293031  

Most Recent Posts


%d bloggers like this: